Kineta, Inc.

As of August 8, 2024, Kineta, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial ratios and a year-to-date stock decline of 27.18%, significantly underperforming compared to the S&P 500.

As of June 18, 2025, Kineta, Inc. exhibits a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearish momentum, despite some mildly bullish signals from MACD and KST, while overall indicators and underperformance against the S&P 500 reinforce the bearish outlook.

Kineta, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $3.66 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of 62.88%.

As of Jun 18, Kineta, Inc. has a market capitalization of 3.66 million, with net sales of 0.00 million and a net profit of -8.45 million over the latest four quarters. Shareholder's funds are at -12.03 million, and total assets are 1.02 million as of Dec 24.